Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Novavax, Inc. logoNovavax, Inc.

NVAX · Nasdaq · USD · Market cap $1.3B · 749 employees

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally.

FAIL · Does not pass the screen
7.47 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price7.47 USD at the 20 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.07x the price, above our 2.00x limit.
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 1.07)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-20).

Current read
Distribution ?
Screened · screened 2026-11-20
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 1.07, read 2026-11-18
  • Ethical does not pass the values gate
Price7.47 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-05Read Distribution10.65-29.9% to today ✓Markup gives way to Distribution after a 6% rise in 4 days
2026-11-01Read Markup10.08-25.9% to today Distribution gives way to Markup first Markup read since October
2026-10-29Read Distribution9.70-23.0% to today ✓Markup gives way to Distribution after a 14% slide in 3 weeks
2026-10-11Read Markup11.32-34.0% to today Accumulation gives way to Markup after a 25% rise in 5 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Novavax, Inc. holds its Distribution at $7.47. The statistical read favours the sellers, held for 13 days.

As held on the ledger · 2026-11-20
PhaseDistribution · caution
Quantitative stateThe statistical read favours the sellers, held for 13 days
Price at the screen$7.47
ValuationN/A trailing · -44.22 forward price to earnings
Values screenFAIL · score 70.0
Beta2.72
The Workings

Five Screens: NVAX's Results

FAIL. Interest-bearing securities

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 21.15% Below 33% Pass
Interest-bearing cash 42.03% Below 33% Fail
Receivables 29.50% Below 49% Pass
Revenue purity 2.63% Below 5% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Novavax,'s business is fine, but its cash and interest-bearing securities are about 42% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when NVAX's ethical verdict changes

Today NVAX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.07x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

Method.

The Street's Range
7.00Street low 16.00Street average 25.00Street high 7.47Price

Street: 9 covering, consensus Buy. Average target +114%.

Chart
The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-44.2x
EPS, trailing-0.52
EPS, forward-0.18
Revenue growth-3.0%revenue is shrinking
Profit margin-18.6%currently unprofitable
FCF yield0.90%
Current ratio2.15comfortably covers its short-term bills
Beta2.72much more volatile than the market
Short interest, float0.28%
52-week range6.20 - 13.39
Market cap$1.3B
Employees749

NVAX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Distribution $7.72 -3.0% Entry 20
2026-11-19 Distribution $7.96 -20.2% Entry 19

Since the last review it saw its composite score ease.

2026-11-12 Distribution $9.98 -6.3% Entry 18
2026-11-05 Distribution · changed $10.65 +10.0% Entry 17

The framework has shifted from markup to distribution since the last review.

2026-11-04 Markup $9.68 -4.0% Entry 16
2026-11-03 Markup $10.08 +0.0% Entry 15
2026-11-02 Markup $10.08 +0.0% Entry 14
2026-11-01 Markup · changed $10.08 +3.9% Entry 13

The framework has shifted from distribution to markup since the last review.

2026-10-31 Distribution $9.70 +0.0% Entry 12
2026-10-30 Distribution $9.70 +0.0% Entry 11

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on NVAX

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in NVAX's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $9.50 -10.3% · $897 -10.3%
2 months $8.12 +4.9% · $1,049 +4.9%
3 months $10.30 -17.3% · $827 -17.3%
6 months $6.69 +27.4% · $1,274 +27.4%
1 year $7.20 +18.3% · $1,183 +18.3%
2 years $16.01 -46.8% · $532 -46.8%
3 years $7.47 +14.1% · $1,141 +14.1%
5 years $209.68 -95.9% · $41 -95.9%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever NVAX does next, these words stay.

Novavax, Inc. · NVAX · Distribution · $7.47
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.